DDInter491 DDInter899
Defibrotide is the sodium salt of a mixture of single-stranded oligodeoxyribonucleotides derived from porcine mucosal DNA. It has been shown to have antithrombotic, anti-inflammatory and anti-ischemic properties (but without associated significant systemic anticoagulant effects). It is marketed under the brand names Dasovas (FM), Noravid, and Prociclide in a variety of countries. In the USA it is was approved in March, 2016 as Defitelio.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Defibrotide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Defibrotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Diflunisal
Defibrotide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Levomilnacipran
Defibrotide {u} may lead to a major life threatening interaction when taken with {v} Ardeparin
Defibrotide {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Defibrotide may cause a minor interaction that can limit clinical effects when taken with Clove
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal
Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Defibrotide may lead to a major life threatening interaction when taken with Ardeparin
Defibrotide may lead to a major life threatening interaction when taken with Fedratinib